ALK-Abelló A/S (ALK-B) Fair Value & Analysis
Healthcare · DK · Market cap 53.4B DKK
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 4 days ago
Share price −5.0% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 175.76 – kr 270.40 · fair‑value band kr 98.08 – kr 163.50 · the kr 237.60 price screens above the kr 130.80 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ALK-Abelló A/S (ALK-B) currently trades at kr 237.60, while our model-based Fair Value estimate is kr 130.80, implying the stock looks roughly 45.0% overvalued today. We read business quality at 75/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, ALK-Abelló A/S generated revenue of 6.6B DKK at a net margin of 19.5%. Revenue grew 16.4% year over year. It earns a return on equity of 20.9%. The balance sheet holds a net cash position of 618M DKK. Fundamentals as of Jul 17, 2026
Our scenario range runs from kr 98.08 (bear case) to kr 163.50 (bull case); at kr 237.60, the current price sits above that range. The share trades about 12% below its 52-week high and 39% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -17% fair-value upside, at -45%, ALK-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ALK-Abelló A/S reported revenue of kr 6.3B in FY2025 versus kr 3.9B in FY2021, a compound +12.7%/yr. Reported net income was kr 1.2B in FY2025, compounding +52.9%/yr from FY2021.
Is ALK-B fairly valued? → Check now
Recent news
- EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at r
- Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close
- Is It Too Late To Consider ALK-Abelló (CPSE:ALK B) After Strong Multi‑Year Gains?
- ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| UCB SA UCB | €239.30 | €179.44 | -25% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$123.32 | A$106.56 | -14% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ALK-Abelló A/S (ALK-B) undervalued?
What is the fair value of ALK-B?
What is the quality score of ALK-B?
What is the revenue of ALK-Abelló A/S (ALK-B)?
What is the net profit margin of ALK-B?
Does ALK-Abelló A/S pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full ALK-Abelló A/S analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.